Abstract
Question addressedIn contrast with pain, dyspnoea is not visible to the general public, who lack the corresponding experiential baggage. We tested the hypothesis that the generalised use of face masks to fight severe acute respiratory syndrome coronavirus 2 dissemination could change this and sensitise people to respiratory health.
MethodsGeneral population polling (1012-person panel demographically representative of the adult French population, quota sampling method; 517 (51%) female). 860 (85%) answered “no” to “treated for a chronic respiratory disease” (“respiratory healthy”), and 152 answered “yes” (“respiratory disease”). 14% of respiratory healthy respondents reported having a close family member treated for a chronic respiratory disease (RH-family+). Respondents described mask-related attitudes, beliefs, inconveniencies, dyspnoea and changes in their respiratory health vision.
ResultsCompliance with masks was high (94.7%). Dyspnoea ranked first among mask inconveniencies (respiratory disease 79.3%, respiratory healthy 67.3%; p=0.013). “Air hunger” was the main sensory dyspnoea descriptor. Mask-related dyspnoea was independently associated with belonging to RH-family+(OR 1.85,95%CI 1.16–2.98)并去除面具以改善呼吸(或5.21,95%CI 3.73–7.28)。它与考虑有效保护他人的掩模是负相关的(或0.42,95%CI 0.25-0.75)。自戴口罩以来,一半的受访者更关心他们的呼吸健康。有41%的人报告更好地了解患者的经历。
Answer to the questionWearing protective face masks leads to the mass discovery of breathing discomfort. It raises public awareness of what respiratory diseases involve and sensitivity to the importance of breathing. These data should be used as the fulcrum of respiratory health oriented communication actions.
Abstract
Wearing COVID-19 face masks has resulted in the discovery of dyspnoea by the general public and heightened concern for respiratory health. This provides the respiratory community with a major communication opportunity.https://bit.ly/3ykpngd
Footnotes
This article has supplementary material available fromwww.qdcxjkg.com
Data from the survey and the corresponding dictionary will be made available to researchers presenting a research project reasonably in phase with the content of the study.
Conflict of interest: L. Serresse has nothing to disclose.
利益冲突:N。Simon-Tillaux没有什么可披露的。
Conflict of interest: M. Decavèle has nothing to disclose.
Conflict of interest: F. Gay has nothing to disclose.
Conflict of interest: N. Nion has nothing to disclose.
Conflict of interest: S. Lavault has nothing to disclose.
Conflict of interest: A. Guerder has nothing to disclose.
Conflict of interest: A. Châtelet is an employee of the IFOP polling institute.
Conflict of interest: F. Dabi is an employee of the IFOP polling institute.
Conflict of interest: A. Demoule reports grants, personal fees and non-financial support from Philips, Respinor and Lungpacer, personal fees from Baxter, Getinge, Lowenstein and Gilead, personal fees and non-financial support from Fisher & Paykel, grants from French Ministry of Health, outside the submitted work.
Conflict of interest: C. Morélot-Panzini reports personal fees for lectures and board membership from AstraZeneca, GSK, SOS Oxygène, ADEP, ISIS, Resmed, Chiesi, Menarini, Vivisol, Air Liquide, Lowenstein, Fisher & Paykel, outside the submitted work.
Conflict of interest: C. Moricot has nothing to disclose.
Conflict of interest: T. Similowski reports personal fees from AstraZeneca France, Boehringer Ingelheim France, TEVA France, Chiesi France, Lungpacer Inc. and ADEP Assistance, personal fees and non-financial support from Novartis France, grants from Air Liquide Medical Systems, outside the submitted work.
- ReceivedMay 23, 2021.
- Accepted2021年8月3日。
- Copyright ©The authors 2022. For reproduction rights and permissions contactpermissions{at}ersnet.org